
Chinese Biotech Firms Eye Global Markets Amid US Regulatory Hurdles
Chinese biotech companies are pursuing global commercialization despite US regulatory barriers, leveraging cost advantages in markets like Europe. Insilico Medicine's Ren Feng highlighted the need for internationalization and the challenge of lacking overseas clinical teams, suggesting business development deals as a solution.


